The second most common lung cancer biomarker for which targeted treatments are available, ALK, is present in 3%–7% of the patients, with the remaining biomarkers for which treatments have been identified all representing under 5% of patients with lung cancer (Halliday et al., 2019). Here, ALK is linked to lung carcinoma.